stockportfolio.pro
Stocks / AMRX vs RDNT
AMRX vs RDNT
Amneal Pharmaceuticals, Inc. and RadNet, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Amneal Pharmaceuticals, Inc. (AMRX) | RadNet, Inc. (RDNT) | |
|---|---|---|
| Market cap | $4.9B | $4.6B |
| Revenue (latest FY) | $3.02B | $2.04B |
| Net income (latest FY) | $72.06M | $-18.65M |
| Revenue growth (5y CAGR) | 8.7% | 13.7% |
| Net margin | 2.4% | -0.9% |
| Return on equity | -101.8% | -1.7% |
| P/E ratio | 41.3 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 3 | 8 |
| Positive free cash flow | Yes | — |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open AMRX — free Open RDNT — freeFrequently asked questions
Which is bigger, AMRX or RDNT?
Amneal Pharmaceuticals, Inc. is larger by market capitalization — $4.9B versus $4.6B.
Which grows faster, AMRX or RDNT?
Over the last five fiscal years, RadNet, Inc. grew revenue faster — 13.7%/yr versus 8.7%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.